Becker muscular dystrophy severity is linked to the structure of dystrophin.

In-frame exon deletions of the Duchenne muscular dystrophy (DMD) gene produce internally truncated proteins that typically lead to Becker muscular dystrophy (BMD), a milder allelic disorder of DMD. We hypothesized that differences in the structure of mutant dystrophin may be responsible for the clinical heterogeneity observed in Becker patients and we studied four prevalent in-frame exon deletions, i.e. Δ45-47, Δ45-48, Δ45-49 and Δ45-51. Molecular homology modelling revealed that the proteins corresponding to deletions Δ45-48 and Δ45-51 displayed a similar structure (hybrid repeat) than the wild-type dystrophin, whereas deletions Δ45-47 and Δ45-49 lead to proteins with an unrelated structure (fractional repeat). All four proteins in vitro expressed in a fragment encoding repeats 16-21 were folded in α-helices and remained highly stable. Refolding dynamics were slowed and molecular surface hydrophobicity were higher in fractional repeat containing Δ45-47 and Δ45-49 deletions compared with hybrid repeat containing Δ45-48 and Δ45-51 deletions. By retrospectively collecting data for a series of French BMD patients, we showed that the age of dilated cardiomyopathy (DCM) onset was delayed by 11 and 14 years in Δ45-48 and Δ45-49 compared with Δ45-47 patients, respectively. A clear trend toward earlier wheelchair dependency (minimum of 11 years) was also observed in Δ45-47 and Δ45-49 patients compared with Δ45-48 patients. Muscle dystrophin levels were moderately reduced in most patients without clear correlation with the deletion type. Disease progression in BMD patients appears to be dependent on the deletion itself and associated with a specific structure of dystrophin at the deletion site.

[1]  E. Blaurock-Busch EDTA: Ethylene Diamine Tetra Acetic Acid – A Review , 2016 .

[2]  K. Flanigan,et al.  Dystrophin as a therapeutic biomarker: Are we ignoring data from the past? , 2014, Neuromuscular Disorders.

[3]  O. Delalande,et al.  The spectrin family of proteins: a unique coiled-coil fold for various molecular surface properties. , 2014, Journal of structural biology.

[4]  Nathalie Jette,et al.  A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy , 2014, Neuromuscular Disorders.

[5]  Y. Takeshima,et al.  A novel splicing silencer generated by DMD exon 45 deletion junction could explain upstream exon 44 skipping that modifies dystrophinopathy , 2014, Journal of Human Genetics.

[6]  V. Vié,et al.  Cholesterol favors the anchorage of human dystrophin repeats 16 to 21 in membrane at physiological surface pressure. , 2014, Biochimica et biophysica acta.

[7]  L. Popplewell,et al.  New developments in the use of gene therapy to treat Duchenne muscular dystrophy , 2014, Expert opinion on biological therapy.

[8]  H. Kan,et al.  Dystrophin levels and clinical severity in Becker muscular dystrophy patients , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  Eric P Hoffman,et al.  Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies. , 2013, Discovery medicine.

[10]  Domenica Taruscio,et al.  The TREAT‐NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia , 2013, Human mutation.

[11]  O. Delalande,et al.  Molecular clues about the dystrophin-neuronal nitric oxide synthase interaction: a theoretical approach. , 2013, Biochemistry.

[12]  J. Verschuuren,et al.  Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  K. Davies,et al.  Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches , 2013, Nature Reviews Genetics.

[14]  F. Leturcq,et al.  Variable phenotype of del45-55 Becker patients correlated with nNOSμ mislocalization and RYR1 hypernitrosylation. , 2012, Human molecular genetics.

[15]  M. Muthu,et al.  The Crystal Structures of Dystrophin and Utrophin Spectrin Repeats: Implications for Domain Boundaries , 2012, PloS one.

[16]  G. Comi,et al.  Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy , 2012, Neurology.

[17]  P. Soler-Palacín,et al.  Complement factor I deficiency: a not so rare immune defect. Characterization of new mutations and the first large gene deletion , 2012, Orphanet Journal of Rare Diseases.

[18]  L. Popplewell,et al.  Genetic therapeutic approaches for Duchenne muscular dystrophy. , 2012, Human gene therapy.

[19]  K. Bushby,et al.  Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. , 2011, Brain : a journal of neurology.

[20]  J. Vissing,et al.  Deletion of exon 26 of the dystrophin gene is associated with a mild Becker muscular dystrophy phenotype , 2011, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[21]  G. Lanfranchi,et al.  SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy , 2011, Neurology.

[22]  O. Delalande,et al.  Computational Study of the Human Dystrophin Repeats: Interaction Properties and Molecular Dynamics , 2011, PloS one.

[23]  J. Ervasti,et al.  Internal deletion compromises the stability of dystrophin. , 2011, Human molecular genetics.

[24]  Anna Carla Turconi,et al.  Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up , 2011, Journal of Neurology.

[25]  D. Cacchiarelli,et al.  miR‐31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy , 2011, EMBO reports.

[26]  S. Winder,et al.  Dystrophin: more than just the sum of its parts. , 2010, Biochimica et biophysica acta.

[27]  Annemieke Aartsma-Rus,et al.  Antisense-mediated modulation of splicing: Therapeutic implications for Duchenne muscular dystrophy , 2010, RNA biology.

[28]  J. T. Dunnen,et al.  Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients , 2010, Neuromuscular Disorders.

[29]  Livija Medne,et al.  Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort , 2009, Human mutation.

[30]  A. Pestronk,et al.  Analysis of Dystrophin Deletion Mutations Predicts Age of Cardiomyopathy Onset in Becker Muscular Dystrophy , 2009, Circulation. Cardiovascular genetics.

[31]  S. Hardy,et al.  Mapping of the lipid-binding and stability properties of the central rod domain of human dystrophin. , 2009, Journal of molecular biology.

[32]  Christophe Béroud,et al.  Genotype–phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD–DMD database: a model of nationwide knowledgebase , 2009, Human mutation.

[33]  Roman G. Efremov,et al.  PLATINUM: a web tool for analysis of hydrophobic/hydrophilic organization of biomolecular complexes , 2009, Bioinform..

[34]  S. Hardy,et al.  A Two-amino Acid Mutation Encountered in Duchenne Muscular Dystrophy Decreases Stability of the Rod Domain 23 (R23) Spectrin-like Repeat of Dystrophin* , 2009, Journal of Biological Chemistry.

[35]  D. Duan,et al.  Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. , 2009, The Journal of clinical investigation.

[36]  J. Chamberlain,et al.  Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. , 2008, Human molecular genetics.

[37]  J. Finsterer,et al.  Cardiac involvement in Becker muscular dystrophy. , 2008, The Canadian journal of cardiology.

[38]  S. Hardy,et al.  Sub-domains of the dystrophin rod domain display contrasting lipid-binding and stability properties. , 2008, Biochimica et biophysica acta.

[39]  F. Muntoni,et al.  Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human , 2007, Neuromuscular Disorders.

[40]  T. Partridge,et al.  Optimizing exon skipping therapies for DMD. , 2007, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[41]  James M. Allen,et al.  Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  J. Ervasti Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. , 2007, Biochimica et biophysica acta.

[43]  M. Schwartz,et al.  Deletion of exon 16 of the dystrophin gene is not associated with disease , 2007, Human mutation.

[44]  Christophe Béroud,et al.  Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy , 2007, Human mutation.

[45]  Edgar Jacoby,et al.  Molecular lipophilicity in protein modeling and drug design. , 2007, Current medicinal chemistry.

[46]  G. van Ommen,et al.  Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame rule , 2006, Muscle & nerve.

[47]  N. Menhart Hybrid spectrin type repeats produced by exon-skipping in dystrophin. , 2006, Biochimica et biophysica acta.

[48]  Simon C Watkins,et al.  Mini-dystrophin efficiently incorporates into the dystrophin protein complex in living cells , 2006, Journal of Muscle Research & Cell Motility.

[49]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[50]  F. Salvatore,et al.  Analysis of Dystrophin Gene Deletions Indicates that the Hinge III Region of the Protein Correlates with Disease Severity , 2005 .

[51]  Alexander D. MacKerell,et al.  Extending the treatment of backbone energetics in protein force fields: Limitations of gas‐phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations , 2004, J. Comput. Chem..

[52]  G. Dickson,et al.  Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins , 2004, Gene Therapy.

[53]  Dongsheng Duan,et al.  Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy , 2002, Nature Medicine.

[54]  Nathan A. Baker,et al.  Electrostatics of nanosystems: Application to microtubules and the ribosome , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[55]  T. Braun,et al.  Heterozygous myogenic factor 6 mutation associated with myopathy and severe course of Becker muscular dystrophy , 2000, Neuromuscular Disorders.

[56]  Alexander D. MacKerell,et al.  All‐atom empirical force field for nucleic acids: I. Parameter optimization based on small molecule and condensed phase macromolecular target data , 2000 .

[57]  Alexander D. MacKerell,et al.  All‐atom empirical force field for nucleic acids: II. Application to molecular dynamics simulations of DNA and RNA in solution , 2000 .

[58]  D. Davis,et al.  Myoferlin, a candidate gene and potential modifier of muscular dystrophy. , 2000, Human molecular genetics.

[59]  L. Anderson,et al.  Multiplex Western blotting system for the analysis of muscular dystrophy proteins. , 1999, The American journal of pathology.

[60]  J. Ervasti,et al.  A Cluster of Basic Repeats in the Dystrophin Rod Domain Binds F-actin through an Electrostatic Interaction* , 1998, The Journal of Biological Chemistry.

[61]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[62]  L. Morandi,et al.  Dystrophin characterization in BMD patients: correlation of abnormal protein with clinical phenotype , 1995, Journal of the Neurological Sciences.

[63]  T. Gibson,et al.  Dystrophin and utrophin: the missing links! , 1995, FEBS letters.

[64]  E. Kahana,et al.  Minimum folding unit of dystrophin rod domain. , 1995, Biochemistry.

[65]  N. Bresolin,et al.  Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. , 1994, Brain : a journal of neurology.

[66]  M. Sippl Recognition of errors in three‐dimensional structures of proteins , 1993, Proteins.

[67]  H. Sweeney,et al.  Dystrophin protects the sarcolemma from stresses developed during muscle contraction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[69]  K. Bushby,et al.  The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy , 1993, Journal of Neurology.

[70]  H Sugita,et al.  Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. , 1991, American journal of human genetics.

[71]  M. Thambyayah,et al.  Prevalence and incidence of Becker muscular dystrophy , 1991, The Lancet.

[72]  K. Davies,et al.  Very mild muscular dystrophy associated with the deletion of 46% of dystrophin , 1990, Nature.

[73]  L. Kunkel,et al.  The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. , 1989, American journal of human genetics.

[74]  A. Monaco,et al.  The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein , 1988, Cell.

[75]  M. Koenig,et al.  Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals , 1987, Cell.

[76]  Annemieke Aartsma-Rus Dystrophin Analysis in Clinical Trials. , 2014, Journal of neuromuscular diseases.

[77]  Bernard Dan,et al.  Pathophysiology of duchenne muscular dystrophy: current hypotheses. , 2007, Pediatric neurology.

[78]  Tae-Jin Song,et al.  Cardiac Assessment in Duchenne and Becker Muscular Dystrophies , 2007 .

[79]  J. Felsenstein Estimation of hominoid phylogeny from a DNA hybridization data set , 2005, Journal of Molecular Evolution.